当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.

Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.

Abstract：

:Smoldering multiple myeloma (SMM) is a biologically heterogeneous, clinically defined entity with a variable rate of progression to symptomatic multiple myeloma (MM). Reliable markers for progression are critical for the development of potential therapeutic interventions. We retrospectively evaluated the predictive value of the evolving pattern of serum M-protein among other progression risk factors in 206 patients with SMM diagnosed between 1973 and 2012. Median time from recognition of evolving type to progression into symptomatic MM was 1.1 years (95% CI 0.5-2.0) and progression rate at 3 years was 71%. Development of the evolving type drastically worsened the prognostic estimation made at diagnosis for every covariate predictive of progression (serum M-protein size, bone marrow plasma cell infiltration, immunoparesis and Mayo Clinic risk). On average, the hazard ratio for progression to symptomatic MM increased to 5.1 (95% CI 3.4-7.6) after recognition of the evolving type. In conclusion, in patients with SMM the evolving pattern accurately predicts the risk of early progression to symptomatic disease, thereby allowing the identification of ultra-high risk patients who would be candidates for immediate therapy.

journal_name

Leukemia

journal_title

Leukemia

authors

Fernández de Larrea C,Isola I,Pereira A,Cibeira MT,Magnano L,Tovar N,Rodríguez-Lobato LG,Calvo X,Aróstegui JI,Díaz T,Lozano E,Rozman M,Yagüe J,Bladé J,Rosiñol L

doi

10.1038/s41375-018-0013-4

subject

Has Abstract

pub_date

2018-06-01 00:00:00

pages

1427-1434

issue

6

eissn

0887-6924

issn

1476-5551

pii

10.1038/s41375-018-0013-4

journal_volume

32

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Genetic, phenotypic and clinical features of acute lymphoblastic leukemias expressing myeloperoxidase mRNA detected by RT-PCR.

    abstract：:Myeloperoxidase (MPO) is found in the azurophilic granules of normal myelocytic cells. Cytochemical staining for MPO activity is used clinically to distinguish myeloid from acute lymphoid leukemias (ALL). However, using a highly sensitive RT-PCR technique, it is possible to detect MPO mRNA in otherwise clear ALL. The ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401305

    authors： Serrano J,Román J,Jiménez A,Castillejo JA,Navarro JA,Sánchez J,García-Castellanos JM,Martín C,Maldonado J,Torres A

    更新日期：1999-02-01 00:00:00

  • A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.

    abstract：:All-trans-retinoic acid (ATRA) is highly active in acute promyelocytic leukemia but not in other types of acute myeloid leukemia (AML). Previously, we showed that ATRA in combination with Lysine-specific demethylase 1 (LSD1) inhibition by tranylcypromine (TCP) can induce myeloid differentiation in AML blasts. This pha...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-0892-z

    authors： Wass M,Göllner S,Besenbeck B,Schlenk RF,Mundmann P,Göthert JR,Noppeney R,Schliemann C,Mikesch JH,Lenz G,Dugas M,Wermke M,Röllig C,Bornhäuser M,Serve H,Platzbecker U,Foerster KI,Burhenne J,Haefeli WE,Müller LP,Bind

    更新日期：2020-06-19 00:00:00

  • VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.

    abstract：:We have previously shown that chronic lymphocytic leukemia (CLL) B cells secrete vascular endothelial growth factor (VEGF) in vitro, have constitutively active VEGF receptors R1 and R2, and respond to exogenous VEGF by specifically upregulating Mcl-1 and XIAP in association with decreased cell death. We found that epi...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403667

    authors： Lee YK,Shanafelt TD,Bone ND,Strege AK,Jelinek DF,Kay NE

    更新日期：2005-04-01 00:00:00

  • Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.

    abstract：:The fms-related tyrosine kinase 3 (FLT3) receptor has been extensively studied over the past two decades with regard to oncogenic alterations that do not only serve as prognostic markers but also as therapeutic targets in acute myeloid leukemia (AML). Internal tandem duplications (ITDs) became of special interest in t...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.257

    authors： Reiter K,Polzer H,Krupka C,Maiser A,Vick B,Rothenberg-Thurley M,Metzeler KH,Dörfel D,Salih HR,Jung G,Nößner E,Jeremias I,Hiddemann W,Leonhardt H,Spiekermann K,Subklewe M,Greif PA

    更新日期：2018-02-01 00:00:00

  • Identification of a favorable subgroup of patients with generalized immunocytomas by follicular dendritic cells.

    abstract：:In the present study, 89 patients with generalized immunocytoma were analyzed retrospectively for the prognostic influence of clinical features and of immunophenotype using bone marrow biopsies. Univariate analysis selected the following variables as significant for survival: age over 60 years (p = 0.021), Rai and Bin...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Eisterer W,Hilbe W,Fend F,Ludescher C,Falk M,Thaler J

    更新日期：1995-02-01 00:00:00

  • Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report.

    abstract：:One-hundred, twenty-eight patients with Hodgkin's disease in remission or who had failed a mechlorethamine, vincristine, procarbazine and prednisone (MOPP), a doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and/or lomustine, etoposide and prednimustine (CEP) regimens have been treated with a high-dose thera...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究

    doi：

    authors： Carella Am,Carlier P,Congiu A,Occhini D,Meloni G,Anselmo AP,Mandelli F,Mazza P,Tura S,Mangoni L

    更新日期：1991-01-01 00:00:00

  • Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission.

    abstract：:In order to improve leukemia-free survival (LFS) without the treatment-related morbidity of allogeneic bone marrow transplantation or multiple prolonged cycles of consolidation chemotherapy, we evaluated the long-term outcome of autologous transplantation of peripheral blood progenitor cells (PBPCs) as postremission t...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403126

    authors： Collisson EA,Lashkari A,Malone R,Paquette R,Emmanouilides C,Territo MC,Schiller GJ

    更新日期：2003-11-01 00:00:00

  • Genomic approaches to small molecule discovery.

    abstract：:With the sequencing of the human genome and the development of new genomic technologies, biomedical discovery has been transformed. The applications of these new approaches are ever-expanding from disease classification, to identification of new targets, to outcome prediction. A logical next step is the integration of...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2009.29

    authors： Stegmaier K

    更新日期：2009-07-01 00:00:00

  • Targeting MYC in multiple myeloma.

    abstract：:Multiple myeloma (MM) is a plasma cell tumor marked by clonal evolution and preceded by a premalignant stage, which progresses via molecular pathway deregulation, including MYC activation. This activation relates to translocation or gain of the MYC locus and deregulation of upstream pathways such as IRF4, DIS3/LIN28B/...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-018-0036-x

    authors： Jovanović KK,Roche-Lestienne C,Ghobrial IM,Facon T,Quesnel B,Manier S

    更新日期：2018-06-01 00:00:00

  • Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia.

    abstract：:Lymphokine-activated killer (LAK) cell activity generated from peripheral blood was tested in 6 patients with typical hairy cell leukemia, 3 not on treatment with alpha-interferon (alpha-IFN) and 3 receiving therapy. In all cases, substantial killing of the LAK-sensitive target Daudi was observed, but hairy cells, whe...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Griffiths SD,Cawley JC

    更新日期：1988-06-01 00:00:00

  • Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.

    abstract：:Lovastatin is an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the major regulatory enzyme of the mevalonate pathway. We have previously reported that lovastatin induces a significant apoptotic response in human acute myeloid leukemia (AML) cells. To identify the critical biochemic...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402196

    authors： Xia Z,Tan MM,Wong WW,Dimitroulakos J,Minden MD,Penn LZ

    更新日期：2001-09-01 00:00:00

  • Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.

    abstract：:In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2014.60

    authors： Dimopoulos MA,Leleu X,Palumbo A,Moreau P,Delforge M,Cavo M,Ludwig H,Morgan GJ,Davies FE,Sonneveld P,Schey SA,Zweegman S,Hansson M,Weisel K,Mateos MV,Facon T,Miguel JF

    更新日期：2014-08-01 00:00:00

  • Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

    abstract：:Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a ...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/leu.2016.299

    authors： Schlenk RF,Stegelmann F,Reiter A,Jost E,Gattermann N,Hebart H,Waller C,Hochhaus A,Platzbecker U,Schafhausen P,Blau IW,Verbeek W,Heidel FH,Werner M,Kreipe H,Teleanu V,Benner A,Döhner H,Grießhammer M,Döhner K

    更新日期：2017-04-01 00:00:00

  • Mesenchymal stem cells in suppression or progression of hematologic malignancy: current status and challenges.

    abstract：:Mesenchymal stem cells (MSCs) are known for being multi-potent. However, they also possess anticancer properties, which has prompted efforts to adapt MSCs for anticancer therapies. However, MSCs have also been widely implicated in pathways that contribute to tumor growth. Numerous studies have been conducted to adapt ...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-018-0373-9

    authors： Lee MW,Ryu S,Kim DS,Lee JW,Sung KW,Koo HH,Yoo KH

    更新日期：2019-03-01 00:00:00

  • NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.

    abstract：:Risk-adjusted treatment stratification in T-cell acute lymphoblastic leukemias (T-ALLs) is currently based only on early response to chemotherapy. We investigated the prognostic implication of hyperactivation of NOTCH pathway resulting from mutations of NOTCH1 or FBXW7 in children with T-ALL enrolled in EORTC-CLG tria...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1038/leu.2010.205

    authors： Clappier E,Collette S,Grardel N,Girard S,Suarez L,Brunie G,Kaltenbach S,Yakouben K,Mazingue F,Robert A,Boutard P,Plantaz D,Rohrlich P,van Vlierberghe P,Preudhomme C,Otten J,Speleman F,Dastugue N,Suciu S,Benoit Y,B

    更新日期：2010-12-01 00:00:00

  • A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

    abstract：:The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Eight hundred and six untreated patients in the UK NCRI AML16 trial with AML/high-risk MDS (median age, 67 years; range 56-84) and norm...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.225

    authors： Burnett AK,Russell NH,Hills RK,Kell J,Nielsen OJ,Dennis M,Cahalin P,Pocock C,Ali S,Burns S,Freeman S,Milligan D,Clark RE

    更新日期：2017-02-01 00:00:00

  • Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.

    abstract：:Relapse of malignant disease remains the major complication in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) with reduced-intensity conditioning (RIC). In this study, we investigated the predictive value of disease-specific markers (DSMs), d...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2010.283

    authors： Lange T,Hubmann M,Burkhardt R,Franke GN,Cross M,Scholz M,Leiblein S,Al-Ali HK,Edelmann J,Thiery J,Niederwieser D

    更新日期：2011-03-01 00:00:00

  • Abnormalities of chromosome 16q in myeloid malignancy: 14 new cases and a review of the literature.

    abstract：:Fourteen patients with abnormalities of chromosome 16q, 13 with acute myelogenous leukaemia (AML), and one with refractory anaemia with excess of blasts (RAEB), are described. Seven patients had inv(16)(p13q22), two had del(16)(q22), and five had other abnormalities of 16q. Six of the seven patients with inv(16) had A...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Betts DR,Rohatiner AZ,Evans ML,Rassam SM,Lister TA,Gibbons B

    更新日期：1992-12-01 00:00:00

  • Faconi anemia and bone marrow clonal chromosome abnormalities.

    abstract：:Clonal chromosome abnormalities were detected in bone marrow cells of 20 patients with Fanconi anemia investigated at various stages of the disease. Two presented with acute leukemia, six with myelodysplastic syndrome, and 12 had minor or no morphological abnormalities of hematopoietic cells. Abnormalities of chromoso...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Maarek O,Jonveaux P,Le Coniat M,Derré J,Berger R

    更新日期：1996-11-01 00:00:00

  • Reconstitution of functional human GM-CSF receptor in mouse NIH3T3 fibroblasts and BA/F3 proB cells.

    abstract：:Granulocyte-macrophage colony-stimulating factor (GM-CSF) plays a critical role in growth and differentiation of myeloid cells. We previously reconstituted high affinity human GM-CSF receptor (hGM-CSFR) in a proB cell line BA/F3 by cotransfecting alpha and beta chain cDNA clones and showed that the reconstituted recep...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Yokota T,Watanabe S,Mui AL,Muto A,Miyajima A,Arai K

    更新日期：1993-08-01 00:00:00

  • Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications.

    abstract：:DH-JH rearrangements of the Ig heavy-chain gene (IGH) occur early during B-cell development. Consequently, they are detected in precursor-B-cell acute lymphoblastic leukemias both at diagnosis and relapse. Incomplete DJH rearrangements have also been occasionally reported in mature B-cell lymphoproliferative disorders...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402964

    authors： González D,Balanzategui A,García-Sanz R,Gutiérrez N,Seabra C,van Dongen JJ,González M,San Miguel JF

    更新日期：2003-07-01 00:00:00

  • Detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reaction.

    abstract：:We used a modification of the polymerase chain reaction (PCR) to amplify the specific bcr-abl mRNA from 14 patients with chronic myeloid leukemia (CML) who had previously received non T cell depleted allogenic bone marrow transplantation (BMT). Two types of reactions were used: a single step amplification with 5' and ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Delfau MH,Kerckaert JP,Collyn d'Hooghe M,Fenaux P,Laï JL,Jouet JP,Grandchamp B

    更新日期：1990-01-01 00:00:00

  • HTLV-I Tax trans-activation and cell growth signaling.

    abstract：:We have cloned two genes for cell surface molecules, capable of delivering the intracellular signals, which are modulated for their expression by Tax. One is the gamma chain of the interleukin-2 (IL-2) receptor which is suggested to be critical for IL-2-dependent growth of human T-cell leukemia virus type I (HTLV-I) i...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Nakamura M,Takasawa N,Ohbo K,Higashimura N,Ohtani K,Tanaka Y,Sugamura K

    更新日期：1997-04-01 00:00:00

  • Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

    abstract：:Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to therapy in chronic myeloid leukaemia (CML). We wanted to determine in what circumstances additional clinically relevant information was provided by simultane...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404139

    authors： Ross DM,Branford S,Moore S,Hughes TP

    更新日期：2006-04-01 00:00:00

  • Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.

    abstract：:Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1-45 years with Philadelphia chromosome-negative ALL according to the NOPHO ALL2008 without cranial irradiation. Overall, 1022 patients were of age 1-9 years (...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.265

    authors： Toft N,Birgens H,Abrahamsson J,Griškevičius L,Hallböök H,Heyman M,Klausen TW,Jónsson ÓG,Palk K,Pruunsild K,Quist-Paulsen P,Vaitkeviciene G,Vettenranta K,Åsberg A,Frandsen TL,Marquart HV,Madsen HO,Norén-Nyström U,Schmi

    更新日期：2018-03-01 00:00:00

  • Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16.

    abstract：:Insertional activation of cellular proto-oncogenes by replication-defective retroviral vectors can trigger clonal dominance and leukemogenesis in animal models and clinical trials. Here, we addressed the leukemogenic potential of vectors expressing interleukin-2 receptor common gamma-chain (IL2RG), the coding sequence...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2008.118

    authors： Modlich U,Schambach A,Brugman MH,Wicke DC,Knoess S,Li Z,Maetzig T,Rudolph C,Schlegelberger B,Baum C

    更新日期：2008-08-01 00:00:00

  • L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia.

    abstract：:The altered metabolism of cancer cells is a treasure trove to discover new antitumoral strategies. The gene (SLC7A5) encoding system L amino-acid transporter 1 (LAT1) is overexpressed in murine lymphoma cells generated via T-cell deletion of the pten tumor suppressor, and also in human T-cell acute lymphoblastic leuke...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.338

    authors： Rosilio C,Nebout M,Imbert V,Griessinger E,Neffati Z,Benadiba J,Hagenbeek T,Spits H,Reverso J,Ambrosetti D,Michiels JF,Bailly-Maitre B,Endou H,Wempe MF,Peyron JF

    更新日期：2015-06-01 00:00:00

  • Genome instability in multiple myeloma.

    abstract：:Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by clonal proliferation of plasma cells and a heterogenous genomic landscape. Copy number and structural changes due to chromosomal instability (CIN) are common features of MM. In this review, we describe how primary and secondary genetic event...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-020-0921-y

    authors： Neuse CJ,Lomas OC,Schliemann C,Shen YJ,Manier S,Bustoros M,Ghobrial IM

    更新日期：2020-11-01 00:00:00

  • ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.

    abstract：:Disruption of pathways leading to programmed cell death plays a major role in most malignancies, including multiple myeloma (MM). ABT-737 is a BH3 mimetic small-molecule inhibitor that binds with high affinity to Bcl-2 and Bcl-xL, preventing the sequestration of proapoptotic molecules and shifting the cell survival/ap...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404719

    authors： Kline MP,Rajkumar SV,Timm MM,Kimlinger TK,Haug JL,Lust JA,Greipp PR,Kumar S

    更新日期：2007-07-01 00:00:00

  • Deletions on der(9) chromosome in adult Ph-positive acute lymphoblastic leukemia occur with a frequency similar to that observed in chronic myeloid leukemia.

    abstract：:The t(9;22)(q34;q11), generating the Philadelphia chromosome (Ph), is found in more than 90% of patients with chronic myeloid leukemia (CML) and in 15-30% of adults with acute lymphoblastic leukemia (ALL). Different groups have recently described the presence of large genomic deletions adjacent to the translocation br...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402829

    authors： Specchia G,Albano F,Anelli L,Storlazzi CT,Zagaria A,Mancini M,Cuneo A,Pane F,Foà R,Manolelli F,Liso V,Rocchi M

    更新日期：2003-03-01 00:00:00